Purespring Therapeutics boasts three gene therapy assets and a platform developed expressly to identify new therapeutic targets to address kidney disease. These assets promise to change the "dialysis or transplant" ultimatums associated with kidney disease, where therapeutic innovation has been scarce. On Business of Biotech, CEO Richard Francis offers a transparent look at the company’s growth strategy and the progress it’s achieved to date. Listen now and subscribe so you never miss an episode.
Explore the experience of selecting and working with a global CDMO partner and the value for one virtual company established to develop the molecular design and process development for a complex protein.
A pharmaceutical company was looking to partner with a CMO with commercial manufacturing capabilities, large-scale assets, multinational sites, and exemplary quality systems and U.S. FDA track records.
Share your perspective on today’s clinical safety and pharmacovigilance environment to inspire global collaborative efforts that fuel innovation in your clinical field. Explore forward-thinking sessions highlighting new technologies that enhance clinical safety, analytical techniques, and patient outcomes. As complex medical products and evolving regulations are introduced into the industry, find your pathway toward optimal success with actionable clinical approaches.